Enanta Pharmaceuticals completes enrollment in two ongoing phase 2 studies
Enanta Pharmaceuticals announced it has completed enrollment in two Phase 2 studies. The Phase 2 study of EDP-938 in RSV is a randomized, double-blind, placebo-controlled, human challenge study in healthy adult subjects randomized into 1 of 2 dosing arms or a placebo arm. March 18, 2019